

REFERENCES

1. Price D. Comparative aspects of development and structure in the prostate. *National Cancer Institute Monogr* 1963; 12:1–25.
2. McNeal JE. Prostate. In: Sternberg SS, ed. *Histology for pathologists*, 2nd ed. Philadelphia: Lippincott–Raven Publishers, 1997; 997–1017.
3. McNeal JE. The zonal anatomy of the prostate. *Prostate* 1981; 2:35–49.
4. McNeal JE. The prostate and prostatic urethra: a morphologic synthesis. *Journal of Urology* 1972;107:1008–1016.
5. Cunha GR, Cooke PS, Bigsby R, et al. Ontogeny of sex steroid receptors in mammals. In: Parker MG, ed. *The structure and function of nuclear hormone receptors*. New York: Academic Press, 1991:235–268.
6. Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. *Endocrine Reviews* 1987;8:338–362.
7. Sugimura Y, Cunha GR, Donjacour AA. Morphogenesis of ductal networks in the mouse prostate. *Biology of Reproduction* 1986;34:961–971.
8. Hayward SW, Baskin LS, Haughney PC, et al. Epithelial development in the rat ventral prostate, anterior prostate and seminal vesicle. *Acta Anatomica* 1996;155:81–93.
9. Hayward SW, Baskin LS, Haughney PC, et al. Stromal development in the ventral prostate, anterior prostate and seminal vesicle of the rat. *Acta Anatomica* 1996;155:94–103.
10. Hayward SW, Brody JR, Cunha GR. An edgewise look at basal cells: Three-dimensional views of the rat prostate, mammary gland and salivary gland. *Differentiation* 1996; 60:219–227.
11. Prins GS. Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. *Endocrinology* 1992;130:2401–2412.
12. Prins GS, Birch L. The developmental pattern of androgen receptor expression in rat prostate lobes is altered after neonatal exposure to estrogen. *Endocrinology* 1995;136:1303–1314.
13. Prins G, Birch L, Greene G. Androgen receptor localization in different cell types of the adult rat prostate. *Endocrinology* 1991;129:3187–3199.

14. Wasserman NF. Benign Prostatic Hyperplasia: A Review and Ultrasound Classification. *Radiologic Clinics of North America* 2006; 44:689-710.
15. Berry S, Coffey D, Walsh P. The Development of Human Benign Prostatic Hyperplasia with Age. *Journal of Urology* 1984;132:474-479.
16. McNeal J, Bostwick D. Intraductal dysplasia: A premalignant lesion of the prostate. *Human Pathology* 1986;17:64-71.
17. Macintosh CA, Stower M., Reid N., Maitland NJ. Precise Microdissection of Human Prostate Cancer Reveals Genotypic Heterogeneity. *Cancer Research* 1998;58(1):23-28.
18. Bostwick DG., Shan A., Qian J et al. Independent origin of multiple foci of prostatic intraepithelial Neoplasia. *Cancer* 1998;83(9):1995-2002.
19. Gleason D. Classification of prostate carcinomas. *Cancer Chemotherapeutic Reports* 1966;50:125-128.
20. Gleason D. The veteran's administration cooperative urologic research group: histologic grading and clinical staging of prostate carcinoma in urologic pathology. *The Prostate* 1977:171-197.
21. Schulz W.A., Burchardt M., Cronauer M.V. Molecular Biology of prostate cancer. 2003;9(8):437-448.
22. Parkin DM, Muir CS, Whelan SL, et al. Cancer incidence in five continents. Lyon: International Agency for Research on Cancer, 1992:45–173.
23. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. *International Journal of Cancer* 1975;15:617–631.
24. Carter BS, Ewing CM, Ward WS, et al. Allelic loss of chromosomes 16q and 10q in human prostate cancer. *Proceedings of National Academy of Sciences of USA* 1990;87:8751–8755.
25. Bova GS, Carter BS, Bussemakers MJ, et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. *Cancer Research* 1993;53:3869–3873.
26. Latil A, Baron JC, Cussenot O, et al. Genetic alterations in localized prostate cancer: identification of a common region of deletion on chromosome arm 18q. *Genes Chromosomes Cancer* 1994;11:119–125.

27. Gao X, Zacharek A, Salkowski A, et al. Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. *Cancer Research* 1995;55:1002–1005.
28. Eagle LR, Yin X, Brothman AR, Williams BJ, et al. Mutation of the MXI1 gene in prostate cancer. *Nature Genetics* 1995;9:249–255.
29. Dong JT, Lamb PW, Rinker-Schaeffer CW, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. *Science* 1995;268:884–886.
30. Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. *Journal of National Cancer Institute* 1993;85:1657–1669.
31. Bookstein R, Rio P, Madreperla SA, et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. *Proceedings of National Academy of Sciences of USA* 1990;87:7762–7766.
32. Askew EB., Gampe RT., Stanley TB., Faggart J/ L., Wilson EM. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. *Journal of Biological Chemistry* 2007:doi:10.1074/jbc.M703268200.
33. Simental JA, Sar M, Lane MV, French FS, and Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor *Journal of Biological Chemistry* 1991 266: 510-518.
34. He B, Gampe RT., Kole AJ., Hnat AT., Stanley TB., An G., Stewart EL., Kalman RI., Minges JT., Wilson EM. Structural Basis for Androgen Receptor Interdomain and Coactivator Interactions Suggests a Transition in Nuclear Receptor Activation Function. 2004; *Molecular Cell* 16:425-438.
35. Van der Kwast TH, Schalken J, De Winter JA, et al. Androgen receptors in endocrine-resistant human prostate cancer. *International Journal of Cancer* 1991;48:189–193.
36. Hobisch A, Culig Z, Radmayr C, et al. Distant metastases from prostatic carcinoma express androgen receptor protein. *Cancer Research* 1995;55:3068–3072.
37. Tilley WD, Lim-Tio SS, Horsfall DJ, et al. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. *Cancer Research* 1994;54:4096–4102.
38. Sadi MV, Barrack ER. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. *Cancer* 1993;71:2574–2580.

39. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. *Biochemical and Biophysical Research Communication* 1990;173:534–540.
40. Tan J, Sharief Y, Hamil KG, et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. *Molecular Endocrinology* 1997;11:450–459.
41. Taplin ME, Budley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. *New England Journal of Medicine* 1995;332:1393–1398.
42. Fenton MA, Shuster TD, Fertig AM, et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. *Clinical Cancer Research* 1997;3:1383–1388.
43. Parada LF, Tabin CJ, Shih C, et al. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. *Nature* 1982;297:474-478.
44. Peehl DM, Wehner N, Stamey TA. Activated Ki-ras oncogene in human prostatic adenocarcinoma. *Prostate* 1987;10: 281–289.
45. Carter BS, Epstein JI, Isaacs WB. ras gene mutations in human prostate cancer. *Cancer Research* 1990;50:6830–6832.
46. Anwar K, Nakakuki K, Shiraishi T, et al. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. *Cancer Research* 1992;52:5991–5996.
47. Konishi N, Enomoto T, Buzard G, et al. K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. *Cancer* 1992;69:2293–2299.
48. Konishi N, Hiasa Y, Tsuzuki T, et al. Comparison of ras activation in prostate carcinoma in Japanese and American men. *Prostate* 1997;30:53–57.
49. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. *Biochimica et Biophysica Acta* 2000;1470:M21–M35.
50. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Acts. *Genes and Development* 1999;13:2905–2927.
51. Ramaswamy S, Nakamura N, Vazquez F, et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-

- kinase/Akt pathway. Proceedings of National Academy of Sciences of USA 1999;96:2110–2115.
52. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor 1 and prostate cancer risk: a population- based case-control study. Journal of National Cancer Institute 1998;90:911–915.
 53. Gray IC, Phillips SM, Lee SJ, et al. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Research 1995;55:4800–4803.
 54. Carter BS, Ewing CM, Ward WS, et al. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proceedings of National Academy of Sciences of USA 1990;87:8751–8755.
 55. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annual Review of Cell and Developmental Biology 2004;20:781-810.
 56. Polakis P. Wnt signaling and cancer. Genes and Development 2000;14:1837–1851.
 57. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000;103:311–320.
 58. Koenman KS., Yeung F., Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39:246-261.
 59. Lin DL., Tarnowski CP., Zhang J., Dai J., Rohn E., Patel AH., Morris MD., Keller ET. Bone metastatic LNCaP derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate2001;47:212-221.
 60. Zhu B, Kyprianou N. Transforming Growth Factor Beta and prostate cancer. Cancer Treatment and Research 2005;126:157-173.
 61. Kim IY, Ahn HJ, Zelner DJ. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clinical Cancer Research 1996;2(8):1255-1261.
 62. Kim IY, Ahn HJ, Zelner DJ,. Expression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during regression. Molecular Endocrinology 1996;10(1):107-115.
 63. Kyprianou N, Isaaca JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988;122(2):552-562.

64. Kyprianou N, Isaacs JT. Expression of transforming growth factor-beta in the rat ventral prostate during castration induced programmed cell death. *Molecular Endocrinology* 1989;3(10):1515-1522.
65. Lucia MS, Sporn MB, Roberts AB. The role of transforming growth factor-beta1, -beta2, and -beta3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells. *Journal of Cell Physiology* 1988;175(2):184-192.
66. Chipuk JE, Cornelius SC, Pultz NJ. The androgen receptor represses transforming growth factor-beta signaling through interaction with smad3. *Journal of Biological Chemistry* 2002;277(2):1240-1248.
67. Hsing AY, Kodamatsu K, Bonham MJ. Regulation of apoptosis induced by transforming growth factor-beta1 in nontumorigenic rat prostatic epithelial cell lines. *Cancer Research* 1996;56(22), 5146-5149.
68. Kundu SD, Kim IY, Yang T. Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)-TGF-beta type II dominant negative receptor. *Prostate* 2000;43(2):118-124.
69. Kim IY, Ahn HJ, Zelner DJ. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissue. *Clinical Cancer Research* 1996;2(8):1255-1261.
70. Williams RH, Stapleton AM, Yang G. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. *Clinical Cancer Research* 1996;2(4):635-640.
71. Kim IY, Ahn HJ, Zelner DJ. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta1 in human prostate cancer cells. *Cancer research* 1996;56(1):44-48.
72. Song K, Cornelius SC, Danielpour D. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II. *Cancer Research* 2003;63(15):4358-4367.
73. Danielpour D. Functions and regulation of transforming growth factor-beta (TGF β) in the prostate. *European Journal of Cancer* 2005;41:846-857.
74. Peehl DM, Sellers RG. Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. *Experimental Cell Research* 1997;232(2):208-215.
75. Bhowmick NA, Chytil A, Plieth D. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. *Science* 2004;303(5659):848-851.

76. Gerdes MJ, Dang TD, Larsen M. Transforming growth factor-beta1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells. *Endocrinology* 1998;139(8):3569-3577.
77. Engel ME, Datta PK, Moses HL. Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. *Journal of Cellular Biochemistry* 1998;31:111-122.
78. Dong C, Li Z, Alvarez Jr. R. Microtubule binding to smads may regulate TGF-beta activity. *Molecular Cell* 2000;5(1):27-34.
79. Shi Y, Wang YF, Jayaraman L. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. *Cell* 1998;94(5):585-594.
80. Charng MJ, Kinnunen P, Hawker J. FKBP-12 recognition is dispensable for signal generation by type I transforming growth factor-beta receptors. *Journal of Biological Chemistry* 1996;271(38):22941-22944.
81. Charng MJ, Zhang D, Kinnunen P. A novel protein distinguishes between quiescent and activated forms of the type I transforming growth factor beta receptor. *Journal of Biological Chemistry* 1998;273(16):9365-9368.
82. Chen YG, Liu F, Massague J. Mechanism of TGFbeta receptor inhibition by FKBP12. *Embo Journal* 1997;16(13):3866-3876.
83. Hu JS, Olson EN. Regulation of differentiation of the BC3H1 muscle cell line through cAMP-dependent and -independent pathways. *Journal of Biological Chemistry* 1988;263(36):19670-19677.
84. Griswold-Prenner I, Kamibayashi C, Maruoka EM. Physical and functional interactions between type I transforming growth factor receptors and Balpha, a WD-40 repeat subunit of phosphatase 2A. *Molecular Cell Biology* 1998;18(11):6595-6604.
85. Reddy KB, Karode MC, Harmony AK. Interaction of transforming growth factor-beta receptors with apolipoprotein J/clusterin. *Biochemistry* 1996;35(1):309-314.
86. Leger JG, Montpetit ML, Tenniswood MP. Characterization and cloning of androgen-repressed mRNAs from rat ventral prostate. *Biochemical and Biophysical Research Communications* 1987;147(1):196-203.
87. Jin G, Howe PH. Transforming growth factor beta regulates clusterin gene expression via modulation of transcription factor c-Fos. *European Journal of Biochemistry* 1999;263(2):534-542.

88. Choy L, Derynck R. The type II transforming growth factor (TGF)-beta receptor interacting protein TRIP-1acts as a modulator of TGF-beta response. *Journal of Biological Chemistry* 1998;273(47):31455-31462.
89. Perlman R, Schiemann WP, Brooks MW. TGF-beta-induced apoptosis mediated by the adapter protein DAXX that facilitates JNK activation. *Nature Cell Biology* 2001;3(8):708-714.
90. Hofmann TG, Stollberg N, Schmitz ML. HIPK2 regulates transforming growth factor-induced c-Jun NH (2)-terminal kinase activation and apoptosis in human hepatoma cells. *Cancer Research* 2003;63(23):8271-8277.
91. Ferrari AC, Seunanez HN, Hannah SM, Atweh GF. A gene that encodes for a leukemia associated phosphoprotein (p18) maps to chromosome bands 1p35-36.1. *Genes Chromosome Cancer* 1990;2:125-129.
92. Pasmantier R, Danoff A, Fleischer N, Schubert UK. P19, a hormonally regulated phosphoprotein of peptide hormone-producing cells: secretagogue-induced phosphorylation in AtT-20mouse pituitary tumor cells and in rat and hamster insulinoma cells. *Endocrinology* 1986;119:1229-1298.
93. Cooper HL, McDuffie E, Braverman R. Human peripheral lymphocyte growth regulation and response to phorbol esters is linked to synthesis and phosphorylation of the cytosolic protein, prosolin. *Journal of Immunology* 1989;143:956-963.
94. Schubert UK, Xu J, Fan W, Cheng G, Goldstein H, Alpini G, Shafritz DA, Amat JA, Farooq M, Norton WT, Owen TA, Lian JB, Stein GS. Widespread and differentiation stage specific expression of the gene encoding phosphoprotein p19 (Metablastin) in mammalian cells. *Differentiation* 1992;51:21-32.
95. Brattsand G, Roos G, Marklan U, Ueda H, Landberg G, Nanberg E, Sideras P, Gulberg M. Quantitative analysis of the expression and regulation of an activation-regulated phosphoprotein (oncoprotein 18) in normal and neoplastic cell. *Leukemia* 1993;7:569-579.
96. Curmi P.A., Noguez C., Lachkar S., Carelle N., Gonthier M.P., Sobel A., Lidereau, and Bieche I; Overexpression of stathmin in breast carcinomas point out to highly proliferative tumors. *British Journal of Cancer* 2000;82: 142-150.
97. Price D.K., Ball J.R., Bahrani-Mostafavi Z., Vachris J.C., Kaufman J.S., Naumann R.W., Higgins R.V. and Hall J.B; The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. *Cancer Investigation* 2000;18:722-730.
98. Mistry S., Atweh G: Role of Stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. *The Mount Sinai Journal of Medicine* 2002;69(5):299-304.

99. Sobel A., Bouterin M.S., Beretta L., Chneiweiss H., Doye V; Intracellular substrates for extracellular signaling. Characterization of a ubiquitous, neuron enriched phosphoprotein (Stathmin). *The Journal of Biological Chemistry* 1989;264(7):3765-3772.
100. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimmers and increases the catastrophic rate of microtubules. *Cell* 1996;84:623-631.
101. Jourdain L, Curmi P, Sobel A, Pantaloni D, Carlier MF. Stathmin: a tubulin-sequestering protein which forms a ternary T2S complex with two tubulin molecules. *Biochemistry* 1997;36:10817-10821.
102. Steinmetz MO, Kammarer RA, Jahnke W, Goldie KN, Lustig A, van Oostrum J. Op18/stathmin caps a kinked photofilament like tubulin tetramer. *Embo Journal* 2000;19:572-580.
103. Giogant B, Curmi PA, Martin-Barbey C, Charbaut E, Lachkar S, Lebeau L, Siavoshian S, Sobel A, Knossow M. The 4 A X-ray structure of a tubulin:stathmin like domain complex. *Cell* 2000;102:809-816.
104. Howell B, Larsson M, Gullberg M, Cassimeris L. Dissociation of tubulin-sequestering and microtubule catastrophe-promoting activities of oncoprotein18/stathmin. *Molecular Biology of Cell* 1999;10:105-118.
105. Brattsand G, Marklund U, Nylander K, Roos G, Gullberg M. Cell-cycle-regulated phosphorylation of oncoprotein 18 on Ser16, Ser25 and Ser38. *European Journal of Biochemistry* 1994;220:359-368.
106. Larsson M, Marklund U, Gradin HM, Brattsand G, Gullberg M. Control of microtubule dynamics by oncoprotein 18, dissection of the regulatory role of multisite phosphorylation during mitosis. *Molecular and Cellular Biology* 1997;17:5530-5539.
107. Larsson N, Melander H, Marklund U, Osterman O, Gullberg M. G2/M transition requires multisite phosphorylation of oncoprotein 18 by two distinct kinase systems. *Journal of Biological Chemistry* 1995;270:14175-14183.
108. Jeha S, Luo XN, Beran M, Kantarjian H, Atweh GF: Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. *Cancer Research* 1996;56(6):1445-1450.
109. Mistry SJ, Bank A, Atweh GF. Targeting stathmin in prostate cancer. *Molecular Cancer Therapeutics*. 2005;4(12):1821-1829.
110. Iancu C., Mistry S., Arkin A., and George F. A. Taxol and anti-stathmin therapy: a synergistic combination that targets the mitotic spindle. *Cancer Research* 2000;60:3537-3541.

111. Ali E., Bash-Babula J., Yang J., and Hait W. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. *Cancer Research* 2002;62:6864-6869.
112. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. *Molecular Cancer Therapeutics* 2006; 5(12):3248-57.
113. Wittmann T, Bokoch GM, Waterman-Storer CM; Regulation of microtubule destabilizing activity of Op18/stathmin downstream of Rac1. *Journal of Biological Chemistry* 2004;279(7):6196-6203.
114. Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou VV, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R.; The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. *Clinical Cancer Research* 2004;10(2):658-67.
115. Meyerhardt JA, Fuchs CS; Epidermal growth factor receptor inhibitors and colorectal cancer. *Oncology (Huntingt)* 2004;(14 Suppl 14):35-38.
116. McCarty M.; Targeting multiple signaling pathways as a strategy for managing prostate cancer:multifocal signal modulation therapy. *Integrative Cancer Therapies* 2004;3(4):349-380.
117. Singh J, Zhu Q, Handelsman DJ. Stereological evaluation of mouse prostate development. *Journal of Andrology* 1999; 20:251-258.
118. Sugimara Y., Cunha G. R., and Donjacour A. A. Morphogenesis of ductal network in the mouse prostate. *Biology of Reproduction* 1986; 34: 961-971.
119. Kasper S. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression and metastasis. *Journal of Cellular Biochemistry* 2005; 94(2): 279-297.
120. Kim MJ, Bhatia-Gaur R., Banach-Petrosky WA, Desai N., Wang Y., Hayward SW., Cunha GR., Cardiff RD., Shen MM., Abate-Shen C. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. *Cancer Research* 2002; 62 (11): 2999-3004.
121. Bhatia-Gaur R., Donjacour AA., Sciavolino PJ., Kim M., Desai N., Young P., Norton CR., Gridley T., Cardiff RD., Cunha GR., Abate-Shen C., Shen MM. Roles for Nkx3.1 in prostate development and cancer. *Genes and Development* 1999; 13(8): 966-977.
122. Wang XD., Shou J., Wong P., French DM., Gao WQ. Notch-1 expressing cells are indispensable for prostatic branching morphogenesis during development and re-growth following castration and androgen replacement. *Journal of Biological Chemistry* 2004; 279(23): 24733-24744.

123. Shou J., Ross S., Koeppen H., Sauvage FJ., Gao WQ. Dynamics of notch expression during murine prostate development and tumorigenesis. *Cancer Research* 2001; 61(19): 7291-7297.
124. Fan L., Pepicelli CV., Dibble CC., Catbagan W., Zarycki JL., Laciak R., Gipp J., Shaw A., Lamm ML., Munoz A., Lipinski R., Thrasher JB., Bushman W. *Endocrinology* 2004; 145 (8): 3961-3970.
125. Kasper S, Sheppard P, Yan Y, Pettigrew N, Borowsky A.D, Prins G, Dodd J.G, Duckworth M.L, Matusik R.J. Development, progression and androgen dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. *Laboratory Investigation* 1998; 78(6): i-xv.
126. Kasper S., Tu W., Roberts RL., Shappell SB. Transgenic mouse models for prostate cancer. Identification of an androgen-dependent promoter and creation and characterization of the long probasin promoter- Large T antigen (LPB-Tag) model. *Methods in Molecular Medicine* 2003; 81: 113-147.
127. Kasper S, Smith J.A. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. *The Journal of Urology* 2004; 172:12-19.
128. Horwitz S.B, Shen H.J, He L, Dittmar P, Neef R, Chen J, Schubert U.K. The microtubule destabilizing activity of metablastin (p19) is controlled by phosphorylation. *The Journal of Biological Chemistry* 1997; 272:8129-8132.
129. Gavet O, Ozon S, Manceau V, Lawler S, Curmi P, Sobel A. The stathmin phosphoprotein family: localization and effects on the microtubule network. *Journal of Cell Sciences* 1998; 111:3333-3346.
130. Wittmann T, Bokoch GM, Waterman-Storer CM. Regulation of microtubule destabilizing activity of Op18/stathmin downstream of Rac1. *Journal of Biological Chemistry* 2004; 279(7):6196-6203.
131. Monet C, Gavard J, Mege R.M, Sobel A. Clustering of cellular prion protein induces ERK1/2 and stathmin phosphorylation in GT1-7 neuronal cells. *FEBS Letter* 2004; 576:114-118.
132. Marklund U, Brattasand G, Shingler V, Gulberg M. Serine 25 of Oncoprotein 18 is a major cytosolic target for the mitogen activated protein kinase. *The Journal of Biological Chemistry* 1993; 268(20):15039-15049.
133. X. Luo, Mookerjee A, Ferrari A, Mistry S, and Atweh G.F. Regulation of phosphoprotein p18 in leukemic cells: cell cycle regulated phosphorylation by p34-cdc2 kinase. *Journal of Biological Chemistry* 1994; 269:10312-10318.
134. Marklund U, Brattasand G, Osterman O, Ohlsson P, Gullberg M. Multiple signal

- transduction pathways induce phosphorylation of serines 16, 25 and 38 in T Lymphocytes. *The journal of Biological Chemistry* 1993; 268(34):25671-25680.
135. Marklund U, Osterman O, Melander H, Bergh A, and Gullberg M. The phenotype of a "Cdc2 kinase target site-deficient" mutant of oncoprotein 18 reveals a role of this protein in cell cycle control. *Journal of biological Chemistry* 1994; 269: 30626-30635.
 136. Curmi PA, Maucuer A, Asselin S, Lecourtois M, Chaffotte A, Schmitter JM, Sobel A. Molecular characterization of human stathmin expressed in *Escherichia coli*: site-directed mutagenesis of two phosphorylatable serines (Ser-25 and Ser-63). *Biochemical Journal* 1994; 300(Pt 2):331-338.
 137. Küntziger T, Gavet O, Sobel A, and Bornens M. Differential Effect of Two Stathmin/Op18 Phosphorylation Mutants on *Xenopus* Embryo Development *Journal of Biological Chemistry*. 2001; 276:22979-22984. Gradin HM, Larsson N, Marklund U, and Gullberg M. Regulation of Microtubule Dynamics by Extracellular Signals: cAMP-dependent Protein Kinase Switches off the Activity of Oncoprotein 18 in Intact Cells. *Journal of Cell Biology*. 1998; 140:131-141.
 138. Gradin HM, Larsson N, Marklund U, and Gullberg M. Regulation of Microtubule Dynamics by Extracellular Signals: cAMP-dependent Protein Kinase Switches off the Activity of Oncoprotein 18 in Intact Cells. *Journal of Cell Biology*. 1998; 140:131-141.
 139. Wang W, Kasper S, Yuan J, Jin RJ, Zhang J, Ishii K, Wills M, Hayward S, Matusik RJ. Androgen-dependent prostate epithelial cell selection by targeting ARR2PBneo to the LPB-Tag model of prostate cancer. *Laboratory Investigation* 2006; 86:1074-1088.
 140. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. *Nature Review Cancer* 2001; 1(1):34-45.
 141. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann A and Mulder E. A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to antiandrogens. *Biochemical and Biophysical Research Communications* 1990; 173(2):534-540.
 142. Hay, E.D. An overview of epithelio-mesenchymal transformation. *Acta Anatomica (Basel)* 1995:154:8-20.
 143. Savagner, P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. *Bioessays* 2001;23:912-23.
 144. Duband, J.L, Monier, F, Delannet, M, Newgreen, D. Epithelium-mesenchyme transition during neural crest development. *Acta Anatomica (Basel)* 1995:154:63-78.

145. Viebahn, C. Epithelio-mesenchymal transformation during formation of the mesoderm in the mammalian embryo. *Acta Anatomica (Basel)* 1995;154:79-97.
146. Veltmaat, J.M. Snail is an immediate early target gene of parathyroid hormone related peptide signaling in parietal endoderm formation. *International Journal of Developmental Biology*. 2000;44:297-307.
147. Birchmeier, C., Birchmeier, W., Brand-Saberi, B. Epithelial-mesenchymal transitions in cancer progression. *Acta Anatomica (Basel)* 1996;156:217-226.
148. Burns WC, Kantharidis P, Thomas MC. The role of tubular epithelial-mesenchymal transition in progressive kidney disease. *Cells Tissues Organs*. 2007;185:222-231.
149. Katoh M. Epithelial-mesenchymal transition in gastric cancer. *International Journal of Oncology*. 2005;27(6):1677-83.
150. Bates RC, Pursell BM, Mercurio AM. Epithelial-mesenchymal transition and colorectal cancer: gaining insights into tumor progression using LIM 1863 cells. *Cells Tissues Organs*. 2007;185(1-3):29-39.
151. Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. *Nature Review Cancer*. 2002;2:442-54.
152. Birchmeier, W, Behrens, J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. *Biochimica Et Biophysica Acta* 1994;1198:11-26.
153. Wheelock, M.J., Soler, A.P., Knudsen, K.A. Cadherin junctions in mammary tumors. *Journal of Mammary Gland Biology and Neoplasia*. 2001;6:275-285.
154. Risinger, J.I., Berchuck, A., Kohler, M.F., Boyd, J. Mutations of the E-cadherin gene in human gynecologic cancers. *Nature Genetics* 1994;7:98-102.
155. Yoshiura, K. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. *Proceedings of National Academy of Sciences of U S A*. 1995;92:7416-7419.
156. Hennig, G. Progression of carcinoma cells is associated with alterations in chromatin structure and factor binding at the E-cadherin promoter in vivo. *Oncogene* 1995;11: 475-484.
157. Hennig, G., Lowrick, O., Birchmeier, W., Behrens, J. Mechanisms identified in the transcriptional control of epithelial gene expression. *Journal of Biological Chemistry* 1996;271:595-602.

158. Hajra, K.M., Ji, X., Fearon, E.R. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. *Oncogene* 1999;18:7274-7279.
159. Rodrigo, I., Cato, A.C., Cano, A. Regulation of E-cadherin gene expression during tumor progression: the role of a new Ets-binding site and the E-pal element. *Experimental Cell Research* 1999;248:358-371.
160. Tamura, G. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. *Journal of National Cancer Institute* 2000;92:569-73.
161. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. *Journal of Cell Biology*. 1994;127:2021-2036.
162. Zavadil J., Bottinger EP. TGF- β and epithelial-to-mesenchymal transitions. *Oncogene*. 2005;24:5764–5774.
163. Zavadil J, Bitzer M, Liang D, Yang YC, Massimi A, Kneitz S, Piek E, Bottinger EP. *Proceedings of National Academy of Sciences of USA*. 2001;98: 6686–6691.
164. Bakin AV., Rinehart C, Tomlinson AK., Arteaga CL. P38 mitogen activated protein kinase is required for TGF β -mediated fibroblastic transdifferentiation and cell migration. *Journal of Cell Science*. 2002;115:3193-3026.
165. Masszi A, Fan L, Rosivall L, McCulloch CA, Rotsteinn OD, Mucsi I, Kapus A. Integrity of cell-cell contacts is a critical regulator of TGF- β 1-induced epithelial-to-myofibroblast transition: role for β -catenin. *American Journal of Pathology* 2004;165:1955-1967.
166. Nawshad A, Hay ED. TGF β ₃ signaling activates transcription of the LEF1 gene to induce epithelial mesenchymal transformation during mouse palate development. *Journal of Cell Biology*. 2003;163:1291-1301.
167. Kim K, Lu Z, Hay ED. Direct evidence for a role of β -catenin/LEF-1 signaling pathway in induction of EMT. *Cell Biology International*. 2002;26:463-476.
168. Huber MA., Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T. NF- κ B is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. *Journal of Clinical Investigation*. 2004;114(4):569-581.
169. Zhou BP., Deng J, Xia W, Xu J, Li YM., Gunduz M, Hung MC. Dual regulation of Snail by GSk-3-mediated phosphorylation in control of epithelial-mesenchymal transition. *Nature Cell Biology*. 2004;6:931-940.

170. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, and Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor-mediated epithelial-to-mesenchymal transition and cell migration. *Journal of Biological Chemistry*. 2000;275:36803-36810.
171. Luo, J. Heterogeneous Expression of Invasive and Metastatic Properties in a Prostate Tumor Model. *Pathology and Oncology Research* 1997;3:264-271.
172. Russell TD, Palmer CA, Orlicky DJ, Fischer A, Rudolph MC, Neville MC, McManaman JL. Cytoplasmic lipid droplet accumulation in developing mammary epithelial cells: roles of adipophilin and lipid metabolism. *Journal of Lipid Research*. 2007;48(7):1463-1475.
173. Jarvis GA, Li J, Hakulinen J, Brady KA, Nordling S, Dahiya R, Meri S. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. *International Journal of Cancer* 1997;71(6):1049-1055.
174. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. *Pathology* 2007;39(3):305-318.
175. Ghosh R, Gu G, Tillman E, Yuan J, Wang Y, Fazli L, Rennie PS, Kasper S. Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. *The Prostate* 2007;67(10):1038-1052.
176. Yu L, Hébert MC, Zhang YE. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. *The EMBO Journal*. 2002;21(14):3749-3759.
177. Chang W. Y., Wilson M. J., Birch L., Prins GS. Neonatal estrogen stimulates proliferation of periductal fibroblasts and alters the extracellular matrix composition in the rat prostate. *Endocrinology* 1999; 140(1): 405-415.
178. Ahn J, Murphy M, Kratowicz S, Wang A, Levine A and George D. Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. *Oncogene* 1999; 18:5954-5958.
179. Johnsen JI, Aurelio ON, Kwaja Z, Jorgensen GE, Pellegata NS, Plattner R, Stanbridge EJ, Cajot J. P-53 mediated negative regulation of stathmin/Op18 expression is associated with G2/M cell-cycle arrest. *International Journal of Cancer* 2000;88:685-691.
180. Wu X, Wu J, Huang J, Powell W, Zhang J, Matusik R, Sangiorgi F, Maxson R, Sucov H and Roy-Burman P. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. *Mechanisms of Development* 2001; 101:61-69.

181. Yan Y, Shephard PC, Kasper S, Lin L, Hoare S, Kapoor A, Dodd JG, Duckworth ML, Matusik RJ. Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. *Prostate* 1997;32(2):129-139.
182. Friedrich B, Gronberg H, Landstorm M, Gullberg M, Bergh A. Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. *Prostate* 1995;27(2):102-109.
183. Upadhyay J, Shekarriz B, Nemeth J. A., Dong Z, Cummings G. D., Fridman R, Sakr W, Grignon D.J., Cher M. L. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. *Clinical Cancer Research* 1999; 5:4105-4110.
184. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. *Prostate* 2000; 42:150-160.
185. Paolo GD, Antonsson B, Kassel D, Riederer BM, Grenningloh G. Phosphorylation regulates the microtubule-destabilizing activity of stathmin and its interaction with tubulin. *FEBS Letters* 1997;416:149-152.
186. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta V. D, Njar V. C. O, Brodie A, Yu L, Veenstra T. D, Chen H, Qiu Y. Regulation of androgen receptor activity by tyrosine phosphorylation. *Cancer Cell* 2006; 10:309-319.
187. Zahedi K, Revelo MP, Barone S, Wang Z, Tehrani K, Citron DP, Bissler JJ, Rabb H, Soleimani M. Stathmin deficient mice develop fibrosis and show delayed recovery from ischemic-reperfusion injury. *American Journal of Physiology: Renal Physiology* 2006;290:F1559-F1567.
188. Brown KA, Aakre ME, Gorska AE, Price JO, Eltom SE, Pietenpol JA, Moses HL. Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. *Breast Cancer Research* 2004;6(3):R215-231.
189. Robson EJ, Khaled WT, Abell K, Watson CJ. Epithelial-to-mesenchymal transition confers resistance to apoptosis in three murine mammary epithelial cell lines. *Differentiation* 2006;74(5):254-264.
190. Lehmann K, Janda E, Pierreux CE, Rytömaa M, Schulze A, McMahon M, Hill CS, Beug H, Downward J. Raf induces TGF production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. *Genes and Development* 2000;14:2610-2622.

191. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. *Genes and Development* 1996;10:2462-2477.
192. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H, Grünert S. Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. *Journal of Cell Biology* 2002;156:299-314.
193. Bhowmick NA, Zent R, Ghiassi M, McDonnell M, Moses HL. Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. *Journal of Biological Chemistry* 2001;276(50):46707-46713.
194. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. *Molecular Biology of Cell* 2001;12(1):27-36.
195. Cui W, Fowles DJ, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. *Cell* 1996;86(4):531-542.
196. Reichmann E, Schwarz H, Deiner EM, Leitner I, Eilers M, Berger J, Busslinger M, Beug H. Activation of an inducible c-FosER fusion protein causes loss of epithelial polarity and triggers epithelial-fibroblastoid cell conversion. *Cell* 1992;71(7):1103-1116.
197. Eger A, Stockinger A, Schaffhauser B, Beug H, Foisner R. Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of beta-catenin and upregulation of beta-catenin/lymphoid enhancer binding factor-1 transcriptional activity. *Journal of Cell Biology* 2000;148(1):173-188.
198. Eger A, Stockinger A, Park J, Langkopf E, Mikula M, Gotzmann J, Mikulits W, Beug H, Foisner R. beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. *Oncogene* 2004;23(15):2672-2680.
199. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, van Roy F. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. *Molecular Cell* 2001;7(6):1267-1278.
200. Bierie B, Moses HL. TGF-beta and cancer. *Cytokine Growth Factor Reviews* 2006;17(1-2):29-40.

201. Holmfeldt P, Brännström K, Stenmark S, Gullberg M. Aneugenic activity of Op18/stathmin is potentiated by the somatic Q18-->e mutation in leukemic cells. *Molecular Biology of Cell* 2006;17(7):2921-2930.
202. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, Isola J, Bendahl PO, Rosen N, Hibshoosh H, Ringnér M, Borg A, Parsons R. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. *Proceedings of National Academy of Sciences of U S A.* 2007;104(18):7564-7569.
203. Oishi Y, Nagasaki K, Miyata S, Matsuura M, Nishimura S, Akiyama F, Iwai T, Miki Y. Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer. *Journal of Human Genetics* 2007;52(3):271-279.